A Phase 1b Study of PRV-300 (JNJ-42915925/CNTO 3157) in patients with moderate to severe ulcerative colitis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
At a glance
- Drugs JNJ 42915925 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept
- Acronyms PULSE
- 23 Oct 2018 According to Provention Bio a media release, top-line data from PULSE is expected in the second quarter of 2019.
- 23 Oct 2018 Status changed from recruiting to active, no longer recruiting, according to a Provention Bio media release.
- 13 Aug 2018 According to Provention Bio a media release, this study has been initiated the first quarter 2018. Top-line data is expected to be available in the second half of 2019.